CA
Capricor Therapeutics, Inc.
CAPR · NASDAQ
$9.06 -2.53% (-$0.23)
1M +37.72%
Market Cap $541.8M
P/E Ratio -
Div. Yield -
ROE 56.60%
Bulios Fair Price
$7.72
14.8% downside
Current Price
$9.06
Undervalued Fair Value Overvalued
According to Bulios Fair Price, CAPR is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
2/9Valuation
95 /100
Cheap EV/EBITDA 0.52x
P/B 2.20x
P/E N/A
Growth
100 /100
Growing Book val. growth 196.04%
EPS growth N/A
FCF growth N/A
Profitability
-
N/A Gross margin N/A
FCF margin N/A
Net margin N/A
Quality
0 /100
Poor ROIC 40.08%
Asset turnover 0.00x
ROE 56.60%
Debt
78 /100
Low Debt/Equity 0.37x
Net debt/EBITDA 0.06x
Current ratio 7.35x
Stability
28 /100
Unstable Beta 0.53x
Profitable years 0
Rev. volatility 545.99%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about CAPR
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Linda Marbán
Employees
231
Headquarters
San Diego
Upcoming events
09 NOV
Earnings
Upcoming earnings report